The pharmacokinetics and pharmacodynamics of iron preparations

Pharmaceutics

Volumn 3, Issue 1, 2011, Pages 12-33

  Geisser, Peter ^a   Burckhardt, Susanna ^a  

^a Vifor (International) Inc   (Switzerland)

Author keywords

Efficacy; Elimination; Iron; Iron complex; Kinetics; Metabolism; Pharmacodynamics; Pharmacokinetics; Safety

Indexed keywords

APOTRANSFERRIN; CERULOPLASMIN; ERYFER; FERRIC CARBOXYMALTOSE; FERRIC CITRATE; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERRIC ION; FERRIC OXIDE; FERRITIN; FERRO SANOL; FERROUS ASCORBATE; FERROUS FUMARATE; FERROUS ION; FERROUS SULFATE; FERUMOXYTOL; IRON DERIVATIVE; IRON DEXTRAN; IRON POLYMALTOSE; IRON SACCHARATE; IRON SORBITEX; MALTOFER; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANAPHYLAXIS; ANEMIA; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG ELIMINATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STABILITY; DYSPEPSIA; ERYTHROCYTE; ERYTHROPOIESIS; HEARTBURN; HUMAN; HYPOTENSION; IRON BLOOD LEVEL; IRON METABOLISM; IRON TRANSPORT; LOW BACK PAIN; MOLECULAR WEIGHT; NAUSEA; OXIDATIVE STRESS; PERIPHERAL EDEMA; REVIEW; TASTE DISORDER; UNSPECIFIED SIDE EFFECT;

EID: 79953724862     PISSN: None     EISSN: 19994923     Source Type: Journal    
DOI: 10.3390/pharmaceutics3010012     Document Type: Review

References (67)

1. Gotloib, L.; Silverberg, D.; Fudin, R.; Shostak, A. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J. Nephrol. 2006, 79, 161-167.
2. Nanas, P.N.; Matsouka, C; Karageorgopoulos, D.; Leonti, A.; Tsolakis, E.; Drakos, S.G.; Tsagalou, E.P.; Maroulidis, G.D.; Alexopoulos, G.P.; Kanakakis, J.E., et al. Etiology of anemia in patients with advanced heart failure. J. Amer. Coll. Cardiol. 2006, 48, 2485-2489.
3. Gasche, C; Lomer, M.C.E.; Cavill, I.; Weiss G. Iron, anaemia, and inflammatory bowel diseases. Gut 2004, 53, 1190-1197.
4. Kalantar-Zadeh, K.; Streja, E.; Miller, J.E.; Nissenson, A.R. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia? Adv. Chronic Kidney Dis. 2009,16, 143-151.
5. Schümann, K.; Classen, H.G.; Hages, M.; Prinz-Langenohl, R.; Pietrzik, K.; Biesalski, H.K. Bioavailability of oral vitamins, minerals, and trace elements in perspective. Drug Res. 1997, 47, 369-380.
6. Andrews, N.C. Disorders of iron metabolism. N. Engl. J. Med. 1999, 341, 1986-1995.
7. Crichton, R.R.; Danielson, B.G.; Geisser, P. Iron Therapy with Special Emphasis on Intravenous Administration, 4th ed.; UNI-MED Verlag AG: Bremen, Germany, 2008.
8. European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products (CPMP). CPMP/EWP/QWP/1401/98. http://faculty.ksu.edu.sa/64448/Documents/EMEA%20Guideline%20BE.pdf. Accessed on 7 July 2010.
9. Wienk, K.J.; Marx, J.J.; Beynen, A.C. The concept of iron and its bioavailability. Eur. J. Nutr. 1999,35,51-75.
10. Beshara, S.; Lundqvist, H.; Sundin, J.; Lubberink, M.; Tolmachev, V.; Valind, S.; Antoni, G.; Langström, B.; Danielson, B.G. Pharmacokinetics and red cell utilization of iron(III)-hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography. Br. J. Haematol. 1999, 104, 296-302.
11. Forth, W. Iron: Bioavailability, Absorption, Utilization; BI Wissenschaftsverlag: Mannheim, Germany, 1992; p. 36.
12. Ekenved, G. Iron Absorption Studies; Munksgaard: Copenhagen, Denmark, 1976.
13. Geisser, P.; Philipp, E. True iron bioavailability, iron pharmacokinetics and clinically silent side effects. Nutr. Immun. Health 2009, 7, 3-11.
14. Danielson, J. Structure, chemistry, and pharmacokinetics of intravenous iron agents. Am. Soc. Nephrol. 2004, 15, S93-S98.
15. Evans, R.W.; Rafique, R.; Zarea, A.; Rapisarda, C; Cammack, R.; Evans, P.J.; Porter, J.B.; Hider, R.C. Nature of non-transferrin-bound iron: studies on iron citrate complexes and the thalassemic sera. J. Biol. Inorg. Chem. 2008, 13, 57-74.
16. Geisser, P. Reactivity of iron compounds (letter). Am. J. Kidney Dis. 2003, 42, 1103-1104.
17. Geisser, P.; Baer, M.; Schaub, E. Structure/histotoxicity relationship of parenteral iron preparations. Drug Res. 1992,42, 1439-1452.
18. Van Wyck, D.; Anderson, J.; Johnson, K. Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrol. Dialysis Transplant. 2004, 19, 561-565.
19. Chandler, G.; Harchowal, J.; Macdougall, I.C. Intravenous iron sucrose: establishing a safe dose. Am. J. Kidney Dis. 2001, 38, 988-991.
20. Danielson, B.G.; Salmonson, T.; Derendorf, H.; Geisser, P. Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Drug Res. 1996, 46, 615-621.
21. Seligman, P.A.; Dahl, N.V.; Strobos, I; Kimko, H.C.; Schleicher, R.B.; Jones, M.; Ducharme, M.P. Single-dose pharmacokinetics of sodium ferric gluconate complex in iron-deficient subjects. Pharmacotherapy 2004, 24, 574-583.
22. Geisser, P.; Banké-Bochita, J. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia. Drug Res. 2010, 60, 362-372.
23. Balakrishnan, V.S.; Rao, M.; Kausz, A.T.; Brenner, L.; Pereira, B.J.; Frigo, T.B.; Lewis, J.M. Physico chemical properties of ferumoxytol, a new intravenous iron preparation. Eur. J. Clin. Invest. 2009, 39, 489-496.
24. Henderson, P.A.; Hillman, R.S. Characteristics of iron dextran utilization in man. Blood 1969, 34, 357-375.
25. Landry, R.; Jacobs, P.M.; Davis, R.; Shenouda, M.; Bolton, W.K. Pharmacokinetics study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients. Am. J. Nephrol. 2005, 25, 400-410.
26. Geisser, P.; Rumyantsev, V. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder. Drug Res. 2010, 60, 373-385.
27. Hentze, M.W.; Muckenthaler, M.U.; Galy, B.; Camaschella, C. Two to tango: regulation of Mammalian iron metabolism. Cell 2010, 142, 24-38.
28. Latunde-Dada, G.O.; Takeuchi, K.; Simpson, R.J.; McKie, A.T. Haem carrier protein 1 (HCP1): Expression and functional studies in cultured cells. FEBSLett. 2006, 580, 6865-6870.
29. Qiu, A.; Jansen, M.; Sakaris, A.; Min, S.H.; Chattopadhyay, S.; Tsai, E.; Sandoval, C; Zhao, R.; Akabas, M.H.; Goldman, I.D. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 2006, 127, 917-928.
30. Nakai, Y.; Inoue, K.; Abe, N.; Hatakeyama, M.; Ohta, K.Y.; Otagiri, M.; Hayashi, Y.; Yuasa, H. Functional characterization of human proton-coupled folate transporter/heme carrier protein 1 heterologously expressed in mammalian cells as a folate transporter. J. Pharmacol. Exp. Ther. 2007, 322, 469-476.
31. Andrew, N.C. When is a heme transporter not a heme transporter? When it's a folate transporter. CellMetab. 2007, 5, 5-6.
32. Ferris, CD.; Jaffrey, S.R.; Sawa, A.; Takahashi, M.; Brady, S.D.; Barrow, R.K.; Tysoe, S.A.; Wolosker, H.; Barañano, D.E.; Doré, S.; et al. Haem oxygenase-1 prevents cell death by regulating cellular iron. Nat. Cell. Biol. 1999, 1, 152-157.
33. Heinrich, H.C.; Gabbe, E.E.; Whang, D.H. Dose relationship of intestinal iron absorption in men with normal iron stores and persons with prelatent/latent iron deficiency. Z. Naturforshg 1969, 24b, 1301-1310.
34. Dresow, B.; Petersen, D.; Fischer, R.; Nielsen, P. Non-transferrin-bound iron in plasma following administration of oral iron drugs. Biometals 2008, 21, 273-276.
35. Hutchinson, C; Al-Ashgar, W.; Liu, D.Y.; Hider, R.C.; Powell, J.J.; Geissler, C.A. Oral ferrous sulphate leads to a marked increase in pro-oxidant nontransferrin-bound iron. Eur. J. Clin. Invest. 2004, 34, 782-784.
36. Macdougall, I.C. Strategies for iron supplementation: oral versus intravenous. Kidney Int. Suppl. 1999, 69, S61-S66.
37. Ekenved, G.; Norrby, A.; Sölvell, L. Serum iron increase as a measure of iron absorption -studies on the correlation with total absorption. Scand. J. Haematol. 1976, 77(Suppl. 28), 31-49.
38. Beutler, E., Buttenwieser, E. The regulation of iron absorption I. a search for humoral factors. J. Lab. Clin. Med. 1960, 55, 274-280.
39. Werner, E.; Kaltwasser, J.P. Judgement of measured values of intestinal iron absorption. Drug Res. 1987,37, 116-121.
40. Heinrich, H.C.; Fischer, R. Correlation of postaborptive serum iron increase and erythrocyte-59Fe-incorporation with the whole body retention of absorbed Fe. Klin. Wochenschr. 1982, 60, 1493-1496.
41. Kaltwasser, J.P.; Werner, E.; Niechzial, M. Bioavailability and therapeutic efficacy of bivalent and trivalent iron preparations. Drug Res. 1987, 37, 122-129.
42. Potgieter, M.A.; Potgieter, J.H.; Venter, C; Venter, J.L.; Geisser, P. Effect of oral aluminium hydroxide on iron absorption from iron(III)-hydroxide polymaltose complex in patients with iron deficiency anemia: A single-centre randomized controlled isotope study. Drug Res. 2007, 57, 392-400.
43. Kaltwasser, J.P.; Hansen, C; Oebike, Y.; Werner, E. Assessment of iron availability using stable 54Fe. Eur. J. Clin. Invest. 1991, 21, 436-442.
44. Geisser, P.; Müller, A. Pharmacokinetics of iron salts and ferric hydroxide-carbohydrate complexes. Drug Res. 1987, 37, 100-104.
45. Jacobs, P.; Johnson, G.; Wood, L. Oral iron therapy in human subjects, comparative absorption between ferrous salts and iron polymaltose. J. Med. 1984, 15, 367-377.
46. Jacobs, P.; Wood, L.; Bird, A.R. Erythrocytes: better tolerance of iron polymaltose complex compared with ferrous sulphate in the treatment of anaemia. Hematology 2000, 5, 77-83.
47. Beshara, S.; Sorensen, J.; Lubberink, M.; Tolmachev, V.; Langström, B.; Antoni, G.; Danielson, B.G.; Lundqvist, H. Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. Br. J. Haematol. 2003, 120, 853-859.
48. Jacobs, P.; Wormald, L.A.; Gregory, M.C. Absorption of iron polymaltose and ferrous sulphate in rats and humans. S. Afr. Med. J. 1979, 55, 1065-1072.
49. Walczyk, T.; Davidsson, L.; Zavaleta, N.; Hurrell, R.F. Stable isotope labels as a tool to determine the iron absorption by Peruvian school children from a breakfast meal. Fresenius J. Anal. Chem. 1997, 359, 445-449.
50. Widness, J.A.; Serfass, R.E.; Haiden, N.; Nelson, S.E.; Lombard, K.A.; Pollak, A. Erythrocyte iron incorporation but not absorption is increased by intravenous iron administration in erythropoietin-treated premature infants. J. Nutr. 2006, 136, 1868-1873.
51. Hallberg, L.; Sölvell, L. Iron absorption studies. ActaMed. Scand. 1960, 168, 3-108.
52. Cantone, M.C.; Molho, N.; Piróla, L.; Gambarini, G.; Hansen, C; Roth, P.; Werner, E. An iron metabolism study in humans by means of stable tracers. Med. Phys. 1988, 15, 862-866.
53. Oudit, G.Y.; Trivieri, M.G; Khaper, N.; Liu, P.P.; Backx, P.H. Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy. J. Mol. Med. 2006, 84, 349-364.
54. Fishbane, S. Iron management in nondialysis-dependent CKD. Am. J. Kidney Dis. 2007, 49, 736-743.
55. Santos, M.; De Sousa, M. In vitro modulation of T-cell surface molecules by iron. Cell. Immunol. 1994, 154, 498-506.
56. Rudd, M.F.; Good, M.F.; Chapman, D.E.; Powell, L.W.; Halliday, J.W. Clonal analysis of the effect of iron on human cytotoxic and proliferation T lymphocytes. Immunol. Cell. Biol. 1990, 68, 317-324.
57. Lyseng-Williamson, K.A.; Keating, G.M. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs 2009, 69, 739-756.
58. Anker, S.D.; Comin Colet, J.C.; Filippatos, G.; Willenheimer, R.; Dickstein, K.; Drexler, H.; Lüscher, T.F.; Bart, B.; Banasiak, W.; Niegowska, J.; et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N. Engl. J. Med. 2009, 361, 2436-2448.
59. Macdougall, I.C.; Ashenden, M. Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medication. Adv. Chronic Kidney Dis. 2009, 6, 117-130.
60. Bailie, G.R.; Clark, J.A.; Lane, CE.; Lane, P.L. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol. Dialysis Transplant. 2005, 20, 1443-1449.
61. Chertow, G.M.; Mason, P.D.; Vaage-Nilsen, O.; Ahlmén, J. Update on adverse drug events associated with parenteral iron. Nephrol. Dialysis Transplant. 2006, 21, 378-382.
62. Lu, M.; Cohen, M.H.; Rieves, D.; Pazdur, R. FDA report: ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am. J. Hematol. 2010, 85, 315-319.
63. Santosh, S.; Podaralla, P.; Miller, B. Anaphylaxis with elevated serum tryptase after administration of intravenous ferumoxytol. Nephrol. Dialysis Transplant. 2010, 3, 341-342.
64. Qunibi, W. Y. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review. Drug Res. 2010, 60, 399-412.
65. Olsson, K.S.; Weinfeld, A. Availability of iron dextran for hemoglobin synthesis. Acta Med. Scand. 1972, 192, 543-549.
66. Tuomainen, T.P.; Nyyssönen, K.; Porkkala-Sarataho, E.; Salonen, R.; Baumgartner, J.A.; Geisser, P.; Salonen, J.T. Oral supplementation with ferrous sulphate but not with non-ionic iron polymaltose complex increases the susceptibility of plasma lipoproteins to oxidation. Nutr. Res. 1999,19, 1121-1132.
67. Geisser, P. Safety and efficacy of iron(III)-hydroxide polymaltose complex/a review of over 25 years experience. Drug Res. 2007, 57, 439-452.